COSMO Pharmaceuticals N.V. (COPN) AI Stock Analysis

• Market Cap: CHF958.07M
• Dividend Yield: 2.9%
• Average Volume (3M): 22.10K
• Price to Earnings (P/E): 7.3
• Beta (1Y): 1.01
• Revenue Growth: 182.25%
• EPS Growth: N/A
• Country: CH
• Employees: 321
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - General
• EPS (TTM): 7.91
• Shares Outstanding: 17,543,522
• 10 Day Avg. Volume: 19,346
• 30 Day Avg. Volume: 22,104
• PEG Ratio: -3.17
• Price to Book (P/B): 2.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 39.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF100.00
• Price Target Upside: 70.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: CHF66.00 ▲(12.44%Upside)

COSMO Pharmaceuticals N.V. demonstrates strong financial performance with significant revenue and profit growth, supported by a robust balance sheet and cash flow generation. The stock's valuation appears attractive with a low P/E ratio and a solid dividend yield. However, the technical analysis indicates overbought conditions, which could temper near-term enthusiasm.

Positive Factors

Cash and Operational Performance

Ending 2024 with €170.4M in cash and equivalents reflects solid operational performance.

Regulatory Approvals

GI Genius poised for further advances with FDA clearance for latest-generation module 300 hardware.

Revenue Growth

Preliminary unaudited revenue demonstrates strength with a 186% year-over-year increase.

Negative Factors

Asset Development Uncertainty

Breezula is considered potentially the highest-value asset for Cosmo, with ongoing clinical development.

Dependence on Approvals

Multiple additional catalysts expected, including potential approval for Winlevi in Europe.

COSMO Pharmaceuticals N.V. Business Overview & Revenue Model

Company Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

How the Company Makes Money

COSMO Pharmaceuticals generates revenue through the development, manufacturing, and commercialization of its proprietary pharmaceutical products, particularly in the gastrointestinal therapeutic area. The company makes money by licensing its technologies and products to other pharmaceutical companies, receiving upfront payments, milestone payments, and royalties on sales. In addition, COSMO Pharmaceuticals collaborates with strategic partners to co-develop and market its products, which helps to expand its market reach and share in the profits generated from these collaborations. The company's focus on innovative drug delivery systems and its robust pipeline of products aim to sustain and grow its revenue streams.

COSMO Pharmaceuticals N.V. Financial Statement Overview

Summary

COSMO Pharmaceuticals N.V. has shown remarkable financial improvements with strong revenue and profit growth. The company maintains a robust balance sheet with minimal debt, high equity, and strong cash flow generation. This financial strength positions the company well for future growth and investment opportunities.

Income Statement

The company demonstrated a significant improvement in financial performance. Gross profit margin improved to 92.56%, and net profit margin rose to 49.94% from negative figures in prior years. Revenue grew by 187.52% from 2023 to 2024, indicating strong operational execution. However, the EBIT and EBITDA margins show a positive trend, reflecting good cost management with EBIT margin at 55.80% and EBITDA margin at 62.11%.

Balance Sheet

The debt-to-equity ratio is low at 0.004, indicating very minimal leverage, which provides financial stability. Return on equity is strong at 26.74%, demonstrating efficient use of equity. The equity ratio is robust at 77.04%, suggesting a strong financial foundation. Overall, the balance sheet reflects a stable financial position with low risk.

Cash Flow

The company's cash flow from operations improved significantly, with a free cash flow growth rate of 755.99% from 2023 to 2024, indicating excellent cash generation capabilities. The operating cash flow to net income ratio is 1.22, and the free cash flow to net income ratio is 1.18, both suggesting strong cash flow in relation to earnings.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	266.79M	92.78M	102.09M	65.07M	60.95M
Gross Profit	246.92M	53.44M	83.33M	49.93M	50.51M
EBITDA	165.71M	19.70M	47.49M	40.48M	7.84M
Net Income	133.24M	-4.93M	17.23M	21.67M	-7.90M
Balance Sheet
Total Assets	646.77M	553.98M	759.59M	805.56M	596.16M
Cash, Cash Equivalents and Short-Term Investments	142.96M	50.27M	240.95M	222.21M	212.85M
Total Debt	2.20M	1.84M	173.60M	169.92M	168.14M
Total Liabilities	141.68M	124.94M	295.80M	292.88M	196.04M
Stockholders Equity	498.33M	422.16M	456.93M	505.28M	400.13M
Cash Flow
Free Cash Flow	156.76M	18.31M	25.92M	4.11M	4.90M
Operating Cash Flow	162.41M	22.71M	33.23M	12.61M	12.98M
Investing Cash Flow	-128.88M	42.30M	1.69M	24.86M	75.45M
Financing Cash Flow	-40.22M	-211.27M	-46.13M	-27.25M	-11.88M

COSMO Pharmaceuticals N.V. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 58.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Positive. The current price of 58.7 is above the 20-day moving average (MA) of 57.62, above the 50-day MA of 52.57, and below the 200-day MA of 59.55, indicating a neutral trend. The MACD of 1.05 indicates Positive momentum. The RSI at 62.77 is Neutral, neither overbought nor oversold. The STOCH value of 50.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:COPN.

COSMO Pharmaceuticals N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COPN	73 Outperform	CHF958.07M	7.33	29.55%	2.90%	182.25%	―
Sector *	46 Neutral	C$192.85M	-4.25	-8.56%	2.91%	13.52%	-1.74%
MLLCF		$152.30M	―	-40.40%	―	―	―
BSLN	75 Outperform	CHF579.56M	7.33		―	32.30%	631.04%
CSBTF		$1.30B	―	-6.44%	―	―	―
NWPHF		$172.18M	11.40		―	―	―
SPHDF		$192.66M	2.70	-93.91%	―	―	―

COSMO Pharmaceuticals N.V. Corporate Events

Cosmo Pharmaceuticals Sets Bold 2030 Vision with AI-Driven Growth

Cosmo Pharmaceuticals N.V. unveiled its ambitious vision for 2030 at the Investor Day 2025, aiming for EUR 480 million in recurring revenues and a 40% EBITDA margin. The company plans to leverage AI-driven growth and innovation, focusing on expanding its core business and digital AI platforms. This strategic roadmap is expected to position Cosmo as a significant player in the future of healthcare, creating value for patients, partners, and shareholders.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Sells ‘Digital Trust’ to Tinexta InfoCert

Cosmo Pharmaceuticals N.V. has announced the sale of its ‘Digital Trust’ division to Tinexta InfoCert for EUR 8.3 million as part of a strategic move to streamline its portfolio. This transaction aligns with Cosmo’s focus on growth in AI-powered medical devices and therapeutics, aiming to enhance its position as an innovation-driven healthcare company. By reallocating resources to core areas, Cosmo seeks sustainable growth and greater benefits for patients and shareholders.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF84.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Launches Pioneering Study Integrating AI with Apple Vision Pro

Cosmo Pharmaceuticals N.V. has announced a groundbreaking clinical study to evaluate the integration of its Medtronic GI Genius™ endoscopy module with Apple Vision Pro at Rush University Medical Center. This innovative approach aims to enhance real-time AI-supported insights during colonoscopy procedures, potentially setting a new standard in interventional medicine. The study’s outcomes will support Cosmo’s FDA approval application, marking a significant step in the fusion of clinical AI and spatial computing in endoscopy.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals’ 2025 General Meeting Approves Dividend Increase

Cosmo Pharmaceuticals N.V. announced the approval of all agenda items at its 2025 general meeting, with shareholders endorsing a 2.5% increase in dividend distribution to EUR 2.05 per share. This decision reflects the company’s commitment to creating long-term value for its stakeholders, as emphasized by the Board Chairman and CEO. The company also plans to provide further insights into its projects at the upcoming Investor Day in Zurich.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Advances AI and GI Drug Development at DDW 2025

Cosmo Pharmaceuticals is actively participating in Digestive Disease Week® 2025 in San Diego, focusing on AI and gastrointestinal drug development. The event serves as a platform for Cosmo to engage with key opinion leaders and potential partners, aiming to strengthen its position in AI-powered endoscopy and GI therapeutics. By convening its AI advisory board, Cosmo demonstrates its commitment to advancing GI care through technology and strategic partnerships, potentially benefiting doctors and patients globally.

Cosmo Pharmaceuticals’ AI-Powered Cerebro Receives EU-MDR Certification

Cosmo Pharmaceuticals announced that Endovision Limited has received EU-MDR certification for Cerebro, a real-time AI-powered guide for esophagogastroduodenoscopy (EGD) procedures. This certification marks a significant advancement in endoscopic imaging, enhancing examination quality and treatment outcomes. The Cerebro software, integrated into the Medtronic GI Genius™ system, uses advanced algorithms to improve the quality of upper gastrointestinal tract interventions, complementing existing solutions for the lower tract. This development aligns with Cosmo’s strategy to integrate AI into clinical practice, offering substantial benefits for patient care and positioning the company as a pioneer in AI-driven endoscopy.

Cosmo Pharmaceuticals Maintains 2025 Financial Forecast Amid CHMP Statement on Winlevi®

Cosmo Pharmaceuticals has confirmed its financial forecast for 2025 remains unchanged despite a recent CHMP statement on the marketing authorization application for Winlevi® in Europe. While disappointed, the company is confident in Winlevi®’s clinical potential and is preparing to request a re-examination, emphasizing its commitment to ensuring patient access in Europe.

Cosmo Pharmaceuticals to Appeal EMA’s Negative Opinion on Winlevi®

Cosmo Pharmaceuticals has announced its intention to appeal a negative recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use regarding the marketing authorization of Winlevi® (Clascoterone Cream 1%) for treating acne vulgaris in Europe. The decision was based on a negative benefit-risk assessment for adolescents, despite positive results in adults. Cosmo argues that the assessment did not appropriately differentiate between these age groups and emphasizes the product’s established safety and efficacy in both clinical studies and real-world use, particularly in the USA. The company remains confident in Winlevi’s potential as a treatment option and plans to engage with the EMA to ensure broader access across Europe.

Cosmo Pharmaceuticals Announces Agenda for 2025 General Meeting

Cosmo Pharmaceuticals has published the agenda for its General Meeting 2025, scheduled for May 30 in Amsterdam. Key items include the approval of the 2024 annual report, a proposal to distribute 2.05 EUR per share from reserves, and the election of board members. This meeting is a platform for reviewing achievements, discussing priorities, and engaging with shareholders, reflecting the company’s commitment to transparency and stakeholder engagement.

Cosmo Pharmaceuticals Appoints New Chief Legal Counsel

Cosmo Pharmaceuticals N.V. has appointed Federico Sommariva as its new Chief Legal Counsel. With extensive experience in the life sciences industry, Sommariva is expected to guide the company through regulatory challenges and support its strategic growth. His appointment is seen as a significant addition to Cosmo’s leadership team, enhancing its capability to navigate the evolving legal landscape and achieve long-term objectives.